Pharmacologic management of duchenne muscular dystrophy: Target identification and preclinical trials

ILAR Journal

Volumn 55, Issue 1, 2014, Pages 119-149

  Kornegay, Joe N ^a   Spurney, Christopher F ^b   Nghiem, Peter P ^b   Brinkmeyer Langford, Candice L ^a   Hoffman, Eric P ^b,c   Nagaraju, Kanneboyina ^b,c  

^a TEXAS A AND M UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Animal models; Drug development; Duchenne muscular dystrophy; Genome wide association studies; Golden retriever muscular dystrophy; Mdx mouse; MRNA arrays; Preclinical studies

Indexed keywords

ANIMAL; DISEASE MODEL; DOG; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG SCREENING; HUMAN; LEGISLATION AND JURISPRUDENCE; MOUSE; MUSCULAR DYSTROPHY, DUCHENNE; PATHOPHYSIOLOGY; PHARMACOGENETICS; PROCEDURES; SPECIES DIFFERENCE; TRANSLATIONAL RESEARCH; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; PHARMACOGENETICS; SPECIES SPECIFICITY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84902474233     PISSN: 10842020     EISSN: 19306180     Source Type: Journal    
DOI: 10.1093/ilar/ilu011     Document Type: Article

References (354)

1. Abdel-Salam E, Abdel-Meguid I, Korraa SS. 2009. Markers of degeneration and regeneration in Duchenne muscular dystrophy. Acta Myol 28:94-100.
2. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL, Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, Guttridge DC. 2007. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 117:889-901.
3. Allen DG, Gervasio OL, Yeung EW, Whitehead NP. 2010. Calcium and the damage pathways in muscular dystrophy. Can J Physiol Pharmacol 88:83-91.
4. Ambrósio CE, Valadares MC, Zucconi E, Cabral R, Pearson PL, Gaiad TP, Canovas M, Vainzof M, Miglino MA, Zatz M. 2008. Ringo, a Golden Retriever Muscular Dystrophy (GRMD) dog with absent dystrophin but normal strength. Neuromuscul Disord 18:892-893.
5. Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, Khurana TS, Fallon JR. 2011. Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci U S A 108:762-767.
6. Anderson JE, Kakulas BA, Jacobsen PF, Johnsen RD, Kornegay JN, Grounds MD. 1993. Comparison of basic fibroblast growth factor in X-linked dystrophin-deficient myopathies of human, dog and mouse. Growth Factors 9:107-121.
7. Angus LM, Chakkalakal JV, Méjat A, Eibl JK, Bélanger G, Megeney LA, Chin ER, Schaeffer L, Michel RN, Jasmin BJ. 2005. Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1a, drives utrophin gene expression at the neuromuscular junction. Am J Physiol Cell Physiol 289:C908-C917.
8. Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T, Takeda S. 2012. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A 109:13763-13768.
9. Araki E, Nakamura K, Nakao K, Kameya S, Kobayashi O, Nonaka I, Kobayashi T, Katsuki M. 1997. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. Biochem Biophys Res Commun 238:492-497.
10. Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M, Morgan JE, van Deutekom JC, Wilton SD, Dickson G, Muntoni F. 2007. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 18:798-810.
11. Arechavala-Gomeza V, Kinali M, Feng L, Guglieri M, Edge G, Main M, Hunt D, Lehovsky J, Straub V, Bushby K, Sewry CA, Morgan JE, Muntoni F. 2010. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials. Neuromuscul Disord 20:295-301.
12. Argyle DJ, Nasir L. 2003. Telomerase: A potential diagnostic and therapeutic tool in canine oncology. Vet Pathol 40:1-7.
13. Arrowsmith J. 2011. Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov 10:328-329.
14. Arthur PG, Grounds MD, Shavlakadze T. 2008. Oxidative stress as a therapeutic target during muscle wasting: considering the complex interactions. Curr Opin Clin Nutr Metab Care 11:408-416.
15. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. 1995. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286-290.
16. Bäckman E, Nylander E, Johansson I, Henriksson KG, Tagesson C. 1988. Selenium and vitamin E treatment of Duchenne muscular dystrophy: No effect on muscle function. Acta Neurol Scand 78:429-435.
17. Badalamente MA, Stracher A. 2000. Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. Muscle Nerve 23:106-111.
18. Baer-Dubowska W, Majchrzak-Celinska A, Cichocki M. 2011. Pharmocoepigenetics: A new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep 63:293-304.
19. Baron D, Dubois E, Bihouée A, Teusan R, Steenman M, Jourdon P, Magot A, Péréon Y, Veitia R, Savagner F, Ramstein G, Houlgatte R. 2011. Metaanalysis of muscle transcriptome data using the MADMuscle database reveals biologically relevant gene patterns. BMC Genomics 12:113.
20. Barrie ES, Smith RM, Sanford JC, Sadee W. 2012. mRNA transcript diversity creates new opportunities for pharmacological intervention. Mol Pharmacol 81:620-630.
21. Barros SP, Offenbacher S. 2009. Epigenetics: Connecting environment and genotype to phenotype and disease. J Dent Res 88:400-408.
22. Barthélémy I, Barrey E, Aguilar P, Uriarte A, Le Chevoir M, Thibaud JL, Voit T, Blot S, Hogrel JY. 2011. Longitudinal ambulatory measurements of gait abnormality in dystrophin-deficient dogs. BMC Musculoskelet Disord 12:75.
23. Barthélémy I, Uriarte A, Drougard C, Unterfinger Y, Thibaud JL, Blot S. 2012. Effects of an immunosuppressive treatment in the GRMD dog model of Duchenne muscular dystrophy. PLoS One 7:e48478.
24. Bartlett RJ, Stockinger S, Denis MM, Bartlett WT, Inverardi L, Le TT, Man NT, Morris GE, Bogan DJ, Metcalf-Bogan J, Kornegay JN. 2000. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat Biotech 18:615-622.
25. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. 1999. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104:375-381.
26. Bello L, Piva L, Barp A, Taglia A, Picillo E, Vasco G, Pane M, Previtali SC, Torrente Y, Gazzerro E, Motta MC, Grieco GS, Napolitano S, Magri F, D'Amico A, Astrea G, Messina S, Sframeli M, Vita GL, Boffi P, Mongini T, Ferlini A, Gualandi F, Soraru' G, Ermani M, Vita G, Battini R, Bertini E, Comi GP, Berardinelli A, Minetti C, Bruno C, Mercuri E, Politano L, Angelini C, Hoffman EP, Pegoraro E. 2012. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology 79:159-162.
27. Benatar M. 2007. Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26:1-13.
28. Benedetti S, Hoshiya H, Tedesco FS. 2013. Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS J 280:4263-4280.
29. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, Cornelio F, Morandi L, Mantegazza R. 1995. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 96:1137-1144.
30. Bertoni C, Lau C, Rando TA. 2003. Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping. Hum Mol Genet 12:1087-1099.
31. Bessou C, Giugia JB, Franks CJ, Holden-Dye L, Ségalat L. 1998. Mutations in the Caenorhabditis elegans dystrophin-like gene dys-1 lead to hyperactivity and suggest a link with cholinergic transmission. Neurogenetics 2:61-72.
32. Betts CA, Wood MJ. 2013. Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy. Curr Pharm Des 19:2948-2962.
33. Binder HJ, Herting DC, Hurst V, Finch SC, Spiro HM. 1965. Tocopherol deficiency in man. N Engl J Med 273:1289-1297.
34. Bird A. 2007. Perceptions of epigenetics. Nature 447:396-398.
35. Bish LT, Sleeper MM, Forbes SC, Morine KJ, Reynolds C, Singletary GE, Trafny D, Pham J, Bogan J, Kornegay JN, Vandenborne K, Walter GA, Sweeney HL. 2011. Long-term systemic myostatin inhibition via livertargeted gene transfer in golden retriever muscular dystrophy. Hum Gene Ther 22:1499-1509.
36. Bish LT, Sleeper MM, Forbes SC, Wang B, Reynolds C, Singletary GE, Trafny D, Morine KJ, Sanmiguel J, Cecchini S, Virag T, Vulin A, Beley C, Bogan J, Wilson JM, Vandenborne K, Kornegay JN, Walter GA, Kotin RM, Garcia L, Sweeney HL. 2012. Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol Ther 20:580-589.
37. Bish LT, Yarchoan M, Sleeper MM, Gazzara JA, Morine KJ, Acosta P, Barton ER, Sweeney HL. 2011. Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLoS One 6:e20856.
38. Blanchet E, Annicotte JS, Pradelli LA, Hugon G, Matecki S, Mornet D, Rivier F, Fajas L. 2012. E2F transcription factor-1 deficiency reduces pathophysiology in the mouse model of Duchenne muscular dystrophy through increased muscle oxidative metabolism. Hum Mol Genet 21:3910-3917.
39. Boddy KN, Roche BM, Schwartz DS, Nakayama T, Hamlin RL. 2004. Evaluation of the six-minute walk test in dogs. Am J Vet Res 65:311-313.
40. Bodensteiner JB, Engel AG. 1978. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567, 000 muscle fibers in 114 biopsies. Neurology. 28:439-446.
41. Bodor M, McDonald CM. 2013. Why short stature is beneficial in Duchenne muscular dystrophy. Muscle Nerve 48:336-342.
42. Bojesen SE. 2013. Telomeres and human health. J Intern Med 274:399-413.
43. Bonuccelli G, Sotgia F, Capozza F, Gazzerro E, Minetti C, Lisanti MP. 2007. Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle 6:1242-1248.
44. Briggs D, Morgan JE. 2013. Recent progress in satellite cell/myoblast engraftment: Relevance for therapy. FEBS J 280:4281-4293.
45. Brinkmeyer-Langford C, Kornegay JN. 2013. Comparative genomics of X-linked muscular dystrophies: The golden retriever model. Curr Genomics 14:330-342.
46. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP, Province MA. 1983. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 6:91-103.
47. Bulfield G, Siller WG, Wight PAL, Moore KJ. 1984. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 81:1189-1192.
48. Burdi R, Rolland JF, Fraysse B, Litvinova K, Cozzoli A, Giannuzzi V, Liantonio A, Camerino GM, Sblendorio V, Capogrosso RF, Palmieri B, Andreetta F, Confalonieri P, De Benedictis L, Montagnani M, De Luca A. 2009. Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: Outcome of a large array of in vivo and ex vivo tests. J Appl Physiol 106:1311-1324.
49. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD Care ConsiderationsWorking Group. 2010. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77-93.
50. Bushby KM, Gardner-Medwin D, Nicholson LV, Johnson MA, Haggerty ID, Cleghorn NJ, Harris JB, Bhattacharya SS. 1993. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. J Neurol 240:105-112.
51. Bushby KM, Hill A, Steele JG. 1999. Failure of early diagnosis in symptomatic Duchenne muscular dystrophy. Lancet 353:557-558.
52. Butcher LM, Beck S. 2008. Future impact of integrated high-throughput methylome analyses on human health and disease. J Genet Genomics 35:391-401.
53. Buyse GM, Van der Mieren G, Erb M, D'hooge J, Herijgers P, Verbeken E, Jara A, Van Den Bergh A, Mertens L, Courdier-Fruh I, Barzaghi P, Meier T. 2009. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: Cardiac protection and improved exercise performance. Eur Heart J 30:116-124.
54. Buyse GM, Goemans N, van den Hauwe M, Thijs D, de Groot IJ, Schara U, Ceulemans B, Meier T, Mertens L. 2011. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul Disord 21:396-405.
55. Carlson CG, Samadi A, Siegel A. 2005. Chronic treatment with agents that stabilize cytosolic IkappaB-alpha enhances survival and improves resting membrane potential in MDX muscle fibers subjected to chronic passive stretch. Neurobiol Dis 20:719-730.
56. Carnwath JW, Shotton DM. 1987. Muscular dystrophy in the mdx mouse: Histopathology of the soleus and extensor digitorum longus muscles. J Neurol Sci 80:39-54.
57. Carpenter JL, Hoffman EP, Romanul FC, Kunkel LM, Rosales RK, Ma NS, Dasbach JJ, Rae JF, Moore FM, McAfee MB, Pearce LK. 1989. Feline muscular dystrophy with dystrophin deficiency. Am J Pathol 135:909-919.
58. Carre-Pierrat M, Lafoux A, Tanniou G, Chambonnier L, Divet A, Fougerousse F, Huchet-Cadiou C, Ségalat L. 2011. Pre-clinical study of 21 approved drugs in the mdx mouse. Neuromuscul Disord 21:313-327.
59. Cerletti M, Negri T, Cozzi F, Colpo R, Andreetta F, Croci D, Davies KE, Cornelio F, Pozza O, Karpati G, Gilbert R, Mora M. 2003. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther 10:750-757.
60. Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA. 2007. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 21:2195-2204.
61. Chamberlain JS, Phelps SF, Cox GA, Maichele AJ, Greenwood A. 1993. PCR analysis of muscular dystrophy in mdx mice. Mol Cell Biol Hum Dis Ser 3:167-189.
62. Chang WJ, Iannaccone ST, Lau KS, Masters BS, McCabe TJ, McMillan K, Padre RC, Spencer MJ, Tidball JG, Stull JT. 1996. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci U S A 93:9142-9147.
63. Chen HC, Cheng SC. 2012. Functional roles of protein splicing factors. Biosci Rep 32:345-359.
64. Chen Y-W, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP. 2005. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65:826-834.
65. Chen Y-W, Zhao P, Borup R, Hoffman EP. 2000. Expression profiling in the muscular dystrophies: Identification of novel aspects of molecular pathophysiology. J Cell Biol 151:1321-1336.
66. Childers MK, Bogan JR, Bogan DJ, Greiner H, Holder M, Grange RW, Kornegay JN. 2012. Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy. Front Pharmacol 2:89.
67. Chiocchetti A, Indelicato M, Bensi T, Mesturini R, Giordano M, Sametti S, Castelli L, Bottarel F, Mazzarino MC, Garbarini L, Giacopelli F, Valesini G, Santoro C, Dianzani I, Ramenghi U, Dianzani U. 2004. High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood 103:1376-1382.
68. Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S. 2013. Muscle type and fiber type specificity in muscle wasting. Int J Biochem Cell Biol 45:2191-2199.
69. Cirak S, Feng L, Anthony K, Arechavala-Gomeza V, Torelli S, Sewry C, Morgan JE, Muntoni F. 2012. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 20:462-467.
70. Clark IA. 1984. Proposed treatment of Duchenne muscular dystrophy with desferrioxamine. Med Hypotheses 13:153-160.
71. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. 2007. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13:204-210.
72. Connolly AM, Schierbecker J, Renna R, Florence J. 2002. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 12:917-925.
73. Consalvi S, Mozzetta C, Bettica P, Germani M, Fiorentini F, Del Bene F, Rocchetti M, Leoni F, Monzani V, Mascagni P, Puri PL, Saccone V. 2013. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med 19:79-87.
74. Cooper BJ, Winand WN, Stedman H, Valentine BA, Hoffman EP, Kunkel LM, Scott M-O, Fischbeck KH, Kornegay JN, Avery RJ, Williams JR, Schmickel RD, Sylvester JE. 1988. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 334:154-156.
75. Cowan J, Macdessi J, Start A, Morgan G. 1980. Incidence of Duchenne muscular dystrophy in New SouthWales and the Australian Capital Territory. J Med Genet 17:245-249.
76. Cozzoli A, Capogrosso RF, Sblendorio VT, Dinardo MM, Jagerschmidt C, Namour F, Camerino GM, De Luca A. 2013. GLPG0492, novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Pharmacol Res 72:9-24.
77. Cozzoli A, Nico B, Sblendorio VT, Capogrosso RF, Dinardo MM, Longo V, Gagliardi S, Montagnani M, De Luca A. 2011. Enalapril treatment discloses an early role of angiotensin II in inflammation-and oxidative stress-related muscle damage in dystrophic mdx mice. Pharmacol Res 64:482-492.
78. Cros D, Harnden P, Pellissier JF, Serratrice G. 1989. Muscle hypertrophy in Duchenne muscular dystrophy. A pathological and morphometric study. J Neurol 236:43-47.
79. Cross SH, Allshire RC, McKay SJ, McGill NI, Cooke HJ. 1989. Cloning of human telomeres by complementation in yeast. Nature 338:771-774.
80. DiMasi JA, Feldman L, Seckler A, Wilson A. 2010. Trends in risks associated with new drug development: Success rates for investigational drugs. Clin Pharmacol Ther 87:272-277.
81. Dai J, Li B, Shi J, Peng L, Zhang D, Qian W, Hou S, Zhao L, Gao J, Cao Z, Zhao J, Wang H, Guo Y. 2010. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother 59:355-366.
82. Decary S, Hamida CB, Mouly V, Barbet JP, Hentati F, Butler-Browne GS. 2000. Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscul Disord 10:113-120.
83. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE. 1997. Utrophindystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90:717-727.
84. Delfín DA, Xu Y, Peterson JM, Guttridge DC, Rafael-Fortney JA, Janssen PM. 2011. Improvement of cardiac contractile function by peptide-based inhibition of NF-κB in the utrophin/dystrophin-deficient murine model of muscular dystrophy. J Transl Med 9:68.
85. De Luca A. 2012. Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: An overview. Acta Myol 31:40-47.
86. Dent KM, Dunn DM, von Niederhausern AC, Aoyagi AT, Kerr L, Bromberg MB, Hart KJ, Tuohy T, White S, den Dunnen JT, Weiss RB, Flanigan KM. 2005. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 134: 295-298.
87. De Paepe B, De Bleecker JL. 2013. Cytokines and chemokines as regulators of skeletal muscle inflammation: Presenting the case of Duchenne muscular dystrophy. Mediators Inflamm 2013:540370.
88. De Palma C, Morisi F, Cheli S, Pambianco S, Cappello V, Vezzoli M, Rovere-Querini P, Moggio M, Ripolone M, Francolini M, Sandri M, Clementi E. 2012. Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis 3:e418.
89. Desguerre I, Mayer M, Leturcq F, Barbet JP, Gherardi RK, Christov C. 2009. Endomysial fibrosis in Duchenne muscular dystrophy: A marker of poor outcome associated with macrophage alternative activation. J Neuropathol Exp Neurol 68:762-773.
90. de Semir D, Aran JM. 2006. Targeted gene repair: The ups and downs of a promising gene therapy approach. Curr Gene Ther 6:481-504.
91. DeVanna JC, Kornegay JN, Bogan DJ, Bogan JR, Dow JL, Hawkins EC. 2014. Respiratory dysfunction in unsedated dogs with golden retriever muscular dystrophy. Neuromuscul Disord 24:63-73.
92. Dominov JA, Kravetz AJ, Ardelt M, Kostek CA, Beermann ML, Miller JB. 2005. Muscle-specific BCL2 expression ameliorates muscle disease in laminina2-deficient, but not in dystrophin-deficient, mice. Hum Mol Genet 14:1029-1040.
93. Duan D. 2006. Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet 15 Spec No 2:R253-R61.
94. Durham WJ, Arbogast S, Gerken E, Li YP, Reid MB. 2006. Progressive nuclear factor-kappaB activation resistant to inhibition by contraction and curcumin in mdx mice. Muscle Nerve 34:298-303.
95. Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, Straub V, Bushby K. 2007. Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 17:470-475.
96. Eccleston A, DeWitt N, Gunter C, Marte B, Nath D. 2007. Epigenetics. Nature 447:395.
97. Edwards RHT, Jones DA, Newham DJ, Chapman SJ. 1984. Role of mechanical damage in the pathogenesis of proximal myopathy in man. Lancet 323:548-552.
98. Edwards SL, Beesley J, French JD, Dunning AM. 2013. Beyond GWASs: Illuminating the dark road from association to function. Am J Hum Genet 93:779-797.
99. Engel AG, Arahata K. 1986. Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 17:704-721.
100. Ergorul C, Levin LA. 2013. Solving the lost in translation problem: Improving the effectiveness of translational research. Curr Opin Pharmacol 13:108-214.
101. Evans NP, Call JA, Bassaganya-Riera J, Robertson JL, Grange RW. 2010. Green tea extract decreases muscle pathology and NF-kappaB immunostaining in regenerating muscle fibers of mdx mice. Clin Nutr 29:391-398.
102. Evans NP, Misyak SA, Robertson JL, Bassaganya-Riera J, Grange RW. 2009. Immune-mediated mechanisms potentially regulate the disease timecourse of duchenne muscular dystrophy and provide targets for therapeutic intervention. PM R 1:755-768.
103. Fairclough RJ, Bareja A, Davies KE. 2011. Progress in therapy for Duchenne muscular dystrophy. Exp Physiol 96:1101-1113.
104. Fan K, Dai J, Wang H, Wei H, Cao Z, Hou S, QianW, Wang H, Li B, Zhao J, Xu H, Yang C, Guo Y. 2008. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum 58:2041-2052.
105. Fan K, Zhang B, Yang H, Wang H, Tan M, Hou S, Qian W, Li B, Wang H, Dai J, Guo Y. 2011. A humanized anti-osteopontin antibody protects from Concanavalin A induced-liver injury in mice. Eur J Pharmacol 657:144-151.
106. Feron M, Guevel L, Rouger K, Dubreil L, Arnaud MC, Ledevin M, Megeney LA, Cherel Y, Sakanyan V. 2009. PTEN contributes to profound PI3 K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle. Am J Pathol 174:1459-1470.
107. Fine DM, Shin JH, Yue Y, Volkmann D, Leach SB, Smith BF, McIntosh M, Duan D. 2011. Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophindeficient dogs. Neuromuscul Disord 21:453-461.
108. Finsterer J, Stöllberger C. 2003. The heart in human dystrophinopathies. Cardiology 99:1-19.
109. Flanigan KM, Campbell K, Viollet L, Wang W, Gomez AM, Walker CM, Mendell JR. 2013. Anti-dystrophin Tcell responses in Duchenne muscular dystrophy: Prevalence and a glucocorticoid treatment effect. Hum Gene Ther 24:797-806.
110. Fleischer S, Sharkey M, Mealey K, Ostrander EA, Martinez M. 2008. Pharmacogenetic and metabolic differences between dog breeds: Their impact on canine medicine and the use of the dog as a preclinical animal model. AAPS J 10:110-119.
111. Foster H, Popplewell L, Dickson G. 2012. Genetic therapeutic approaches for Duchenne muscular dystrophy. Hum Gene Ther 23:676-687.
112. Gamstorp I, Gustavson KH, Hellström O, Nordgren B. 1986. A trial of selenium and vitamin E in boys with muscular dystrophy. J Child Neurol 1:211-214. Erratum in: New Eng J Med 2011; 365:1361.
113. Gaschen F, Gaschen L, Seiler G, Welle M, Jaunin VB, Jmaa DG, Neiger-Aeschbacher G, Adé-Damilano M. 1998. Lethal peracute rhabdomyolysis associated with stress and general anesthesia in three dystrophin-deficient cats. Vet Pathol 35:117-123.
114. Gaschen FP, Hoffman EP, Gorospe JR, Uhl EW, Senior DF, Cardinet GH 3rd, Pearce LK. 1992. Dystrophin deficiency causes lethal muscle hypertrophy in cats. J Neurol Sci 110:149-159.
115. Gazzerro E, Assereto S, Bonetto A, Sotgia F, Scarfì S, Pistorio A, Bonuccelli G, Cilli M, Bruno C, Zara F, Lisanti MP, Minetti C. 2010. Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol 176:1863-1877.
116. Gehrig SM, van der Poel C, Hoeflich A, Naim T, Lynch GS, Metzger F. 2012. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy. Growth Horm IGF Res 22:69-75.
117. Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, Ravazzolo R. 2004. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 20:87-96.
118. Gibbs EM, Horstick EJ, Dowling JJ. 2013. Swimming into prominence: The zebrafish as a valuable tool for studying human myopathies and muscular dystrophies. FEBS J 280:4187-4197.
119. Gillis JM. 1999. Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse. J Muscle Res Cell Motil. 20:605-625.
120. Giordani L, Puri PL. 2013. Epigenetic control of skeletal muscle regeneration: Integrating genetic determinants and environmental changes. FEBS J 280:4014-4025.
121. Giorgio V, Soriano ME, Basso E, Bisetto E, Lippe G, Forte MA, Bernardi P. 2010. Cyclophilin D in mitochondrial pathophysiology. Biochim Biophys Acta 1797:1113-1118.
122. Godin R, Daussin F, Matecki S, Li T, Petrof BJ, Burelle Y. 2012. Peroxisome proliferator-activated receptor γ coactivator1-gene α transfer restores mitochondrial biomass and improves mitochondrial calcium handling in post-necrotic mdx mouse skeletal muscle. J Physiol 590:5487-5502.
123. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, Sitsen JM, Aartsma-Rus A, van Ommen GJ, Buyse G, Darin N, Verschuuren JJ, Campion GV, de Kimpe SJ, van Deutekom JC. 2011. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364:1513-1522. Erratum in: N Engl J Med 365:1361.
124. Gorospe JR, Tharp MD, Hinckley J, Kornegay JN, Hoffman EP. 1994. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J Neurol Sci 122:44-56.
125. Gosselin LE, Williams JE. 2006. Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle. Muscle Nerve 33:820-823.
126. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA. 2004. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 30:645-653.
127. Gosselin LE, Williams JE, Personius K, Farkas GA. 2007. A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: Impact of pirfenidone. Muscle Nerve 35:208-216.
128. Graham IR, Dickson G. 2002. Gene repair and mutagenesis mediated by chimeric RNA-DNA oligonucleotides: Chimeraplasty for gene therapy and conversion of single nucleotide polymorphisms (SNPs). Biochim Biophys Acta 1587:1-6.
129. Graham KM, Singh R, Millman G, Malnassy G, Gatti F, Bruemmer K, Stefanski C, Curtis H, Sesti J, Carlson CG. 2010. Excessive collagen accumulation in dystrophic (mdx) respiratory musculature is independent of enhanced activation of the NF-kappaB pathway. J Neurol Sci 294:43-50.
130. Granchelli JA, Pollina C, Hudecki MS. 2000. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 10:235-239.
131. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, Cwik VA, Pandya S, Robison J, King W, Signore L, Schierbecker J, Florence J, Mateson-Burden N, Wilson B. 1993. Duchenne dystrophy: Randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43:520-527.
132. Griggs RC, Rennie MJ. 1983. Muscle wasting in muscular dystrophy: Decreased protein synthesis or increased degradation? Ann Neurol 13:125-132.
133. Grounds MD. 2008. Two-tiered hypotheses for Duchenne muscular dystrophy. Cell Mol Life Sci 65:1621-1625.
134. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A. 2008. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 31:1-19.
135. Guerron AD, Rawat R, Sali A, Spurney CF, Pistilli E, Cha HJ, Pandey GS, Gernapudi R, Francia D, Farajian V, Escolar DM, Bossi L, Becker M, Zerr P, de la Porte S, Gordish-Dressman H, Partridge T, Hoffman EP, Nagaraju K. 2010. Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. PLoS One 5:e11220.
136. Guevel L, Lavoie JR, Perez-Iratxeta C, Rouger K, Dubreil L, Feron M, Talon S, Brand M, Megeney LA. 2011. Quantitative proteomic analysis of dystrophic dog muscle. J Proteome Res 10:2465-2478.
137. Gurnaney H, Brown A, Litman RS. 2009. Malignant hyperthermia and muscular dystrophies. Anesth Analg 109:1043-1048.
138. Hackam DG, Redelmeier DA. 2006.Translation of research evidence from animals to humans. JAMA 296:1731-1732.
139. Haslett JN, Sanoudou D, Kho AT, Bennett RR, Greenberg SA, Kohane IS, Beggs AH, Kunkel LM. 2002. Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci U S A:15000-15005.
140. Haslett JN, Sanoudou D, Kho AT, Han M, Bennett RR, Kohane IS, Beggs AH, Kunkel LM. 2003. Gene expression profiling of Duchenne muscular dystrophy skeletal muscle. Neurogenetics 163-171.
141. Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van derMeulen JH, Sali A, Miller BK, Phadke A, Scheffer L, Quinn J, Tatem K, Jordan S, Dadgar S, Rodriguez OC, Albanese C, Calhoun M, Gordish-Dressman H, Jaiswal JK, Connor EM, McCall JM, Hoffman EP, Reeves EK, Nagaraju K. 2013. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 5:1569-1585.
142. Henderson VC, Kimmelman J, Fergusson D, Grimshaw JM, Hackam DG. 2013. Threats to validity in the design and conduct of preclinical efficacy studies: A systematic review of guidelines for in vivo animal experiments. PLoS Med 10:e1001489.
143. Henriques-Pons A, Yu Q, Rayavarapu S, Cohen TV, Ampong B, Cha HJ, Jahnke V, Van der Meulen J, Wang D, Jiang W, Kandimalla ER, Agrawal S, Spurney CF, Nagaraju K. 2014. Role of toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Hum Mol Genet Jan 14. [Epub ahead of print].
144. Heslop L, Morgan JE, Partridge TA. 2000. Evidence for a myogenic stem cell that is exhausted in dystrophic muscle. J Cell Sci 113:2299-2308.
145. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL. 2007. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single-and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47:430-444.
146. Hnia K, Gayraud J, Hugon G, Ramonatxo M, De La Porte S, Matecki S, Mornet D. 2008. L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol 172:1509-1519.
147. Hoffman EP, Brown RH, Kunkel LM. 1987. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51:919-928.
148. Hoffman EP, Brown KJ, Eccleston E. 2003. New molecular research technologies in the study of muscle disease. Curr Opin Rheumatol 15:698-707.
149. Hoffman EP, Connor EM. 2013. Orphan drug development in muscular dystrophy: Update on two large clinical trials of dystrophin rescue therapies. Discov Med 16:233-239.
150. Hoffman EP, Gordish-Dressman H, McLane VD, Devaney JM, Thompson PD, Visich P, Gordon PM, Pescatello LS, Zoeller RF, Moyna NM, Angelopoulos TJ, Pegoraro E, Cox GA, Clarkson PM. 2013. Alterations in osteopontin modify muscle size in females in both humans and mice. Med Sci Sports Exerc 45:1060-1068.
151. Hoffman EP, Gorospe RM. 1991. The animal models of Duchenne muscular dystrophy: Windows on the pathophysiological consequences of dystrophin deficiency. Curr Top Membranes 38:113-155.
152. Hollinger K, Yang CX, Montz RE, Nonneman D, Ross JW, Selsby JT. 2013a. Dystrophin insufficiency causes selective muscle histopathology and loss of dystrophin-glycoprotein complex assembly in pig skeletal muscle. FASEB J 2013 Dec 17 [Epub ahead of print].
153. Hollinger K, Gardan-Salmon D, Santana C, Rice D, Snella E, Selsby JT. 2013b. Rescue of dystrophic skeletal muscle by PGC-1a involves restored expression of dystrophin-associated protein complex components and satellite cell signaling.AmJ Physiol Regul Integr Comp Physiol 305: R13-R23.
154. Holysz H, Lipinska N, Paszel-Jaworska A, Rubis B. 2013. Telomerase as a useful target in cancer fighting-the breast cancer case. Tumour Biol 34:1371-1380.
155. Hou L, Zhao H. 2013. A review of post-GWAS prioritization approaches. Front Genet 4:280.
156. Huang P, Cheng G, Lu H, Aronica M, Ransohoff RM, Zhou L. 2011. Impaired respiratory function in mdx and mdx/utrn(+/-) mice. Muscle Nerve 43:263-267.
157. Hübner C, Lehr HA, Bodlaj R, Finckh B, Oexle K, Marklund SL, Freudenberg K, Kontush A, Speer A, Terwolbeck K, Voit T, Kohlschütter A. 1996. Wheat kernel ingestion protects from progression of muscle weakness in mdx mice, an animal model of Duchenne muscular dystrophy. Pediatr Res 40:444-449.
158. Hunter AJ. 2011. Have animal models of disease helped or hindered the drug discovery process? Ann N YAcad Sci 1245:1-2.
159. Huynh T, Uaesoontrachoon K, Quinn JL, Tatem KS, Heier CR, Van Der Meulen JH, Yu Q, Harris M, Nolan CJ, Haegeman G, Grounds MD, Nagaraju K. 2013. Selective modulation through the glucocorticoid receptor ameliorates muscle pathology in mdx mice. J Pathol 231:223-235.
160. Iannitti T, Capone S, Feder D, Palmieri B. 2010. Clinical use of immunosuppressants in Duchenne muscular dystrophy. J Clin Neuromuscul Dis 12:1-21.
161. Inkley SR, Oldenburg FC, Vignos PJ Jr. 1974. Pulmonary function in Duchenne muscular dystrophy related to stage of disease. Am J Med 56:297-306.
162. Jahnke VE, Van Der Meulen JH, Johnston HK, Ghimbovschi S, Partridge T, Hoffman EP, Nagaraju K. 2012. Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Skelet Muscle 2:16.
163. Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC. 2007. Osteopontin: An emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 11:81-90.
164. Jejurikar SS, Kuzon WM Jr. 2003. Satellite cell depletion in degenerative skeletal muscle. Apoptosis 8:573-578.
165. Jones DA, Round JM, Edwards RHT, Grindwood SR, Tofts PS. 1983. Size and composition of the calf and quadriceps muscles in Duchenne muscular dystrophy. A tomographic and histochemical study. J Neurol Sci 60:307-322.
166. Kakulas BA. 1975. Experimental muscle diseases. Methods Achiev Exp Pathol 7:109-131.
167. Karpati G, Carpenter S, Morris GE, Davies KE, Guerin C, Holland P. 1993. Localization and quantitation of the chromosome 6-encoded dystrophinrelated protein in normal and pathological human muscle. J Neuropathol Exp Neurol 52:119-128.
168. Karpati G, Carpenter S, Prescott S. 1988. Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 11:795-803.
169. Kharraz Y, Guerra J, Mann CJ, Serrano AL, Muñoz-Cánoves P. 2013. Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators Inflamm 2013:491497.
170. Khurana TS, Watkins SC, Chafey P, Chelly J, Tomé FM, Fardeau M, Kaplan JC, Kunkel LM. 1991. Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscul Disord 1:185-189.
171. Kipling D, Cooke HJ. 1990. Hypervariable ultra-long telomeres in mice. Nature 347:400-402.
172. Kissel JT, Lynn DJ, Rammohan KW, Klein JP, Griggs RC, Moxley RT 3rd, Cwik VA, Brooke MH, Mendell JR. 1993. Mononuclear cell analysis of muscle biopsies in prednisone-and azathioprine-treated Duchenne muscular dystrophy. Neurology 43:532-536.
173. Klingler W, Jurkat-Rott K, Lehmann-Horn F, Schleip R. 2012. The role of fibrosis in Duchenne muscular dystrophy. Acta Myol 31:184-195.
174. Klymiuk N, Blutke A, Graf A, Krause S, Burkhardt K, Wuensch A, Krebs S, Kessler B, Zakhartchenko V, Kurome M, Kemter E, Nagashima H, Schoser B, Herbach N, Blum H, Wanke R, Aartsma-Rus A, Thirion C, Lochmüller H, Walter MC, Wolf E. 2013. Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum Mol Genet 22:4368-4382.
175. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715.
176. Konieczny P, Swiderski K, Chamberlain JS. 2013. Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve 47:649-663.
177. Kornegay JN, Bogan DJ, Bogan JR, Childers MK, Cundiff DD, Petroski GF, Schueler RO. 1999. Contraction force generated by tibiotarsal joint flexion and extension in dogs with golden retriever muscular dystrophy. J Neurol Sci 166:115-121.
178. Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Grange RW. 2011. Golden retriever muscular dystrophy (GRMD): Developing and maintaining a colony and physiological functional measurements. In Duan D, ed. Muscle Gene Therapy: Methods and Protocols. Methods in Molecular Biology. 709th vol. New York: Humana Press. p 105-123.
179. Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P, Detwiler DA, Larsen CA, Grange RW, Bhavaraju-Sanka RK, Tou S, Keene BP, Howard JF Jr, Wang J, Fan Z, Schatzberg SJ, Styner MA, Flanigan KM, Xiao X, Hoffman EP. 2012a. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome 23:85-108.
180. Kornegay JN, Childers MK, Bogan DJ, Bogan JR, Nghiem P, Wang J, Fan Z, Howard JF Jr, Schatzberg SJ, Dow JL, Grange RW, Styner MA, Hoffman EP, Wagner KR. 2012b. The paradox of muscle hypertrophy in muscular dystrophy. In: Carter GT (ed). Recent Advancements in Neuromuscular Medicine. Phys Med Rehabil Clin N Am 23:149-172.
181. Kornegay JN, Cundiff DD, Bogan DJ, Bogan JR, Okamura CS. 2003. The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy. Neuromuscul Disord 13:493-500.
182. Kornegay JN, Li J, Bogan JR, Bogan DJ, Chen C, Zheng H, Wang B, Qiao C, Howard JF Jr, Xiao X. 2010.Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 18:1501-1508.
183. Kornegay JN, Tuler SM, Miller DM, Levesque DC. 1988. Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 11:1056-1064.
184. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. 2012. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490:187-191.
185. Law DJ, Allen DL, Tidball JG. 1994. Talin, vinculin and DRP (utrophin) concentrations are increased at mdx myotendinous junctions following onset of necrosis. J Cell Sci 107:1477-1483.
186. Lawler JM. 2011. Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy. J Physiol 589:2161-2170.
187. Lee S-J. 2004. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20:61-86.
188. Lefaucheur JP, Pastoret C, Sebille A. 1995. Phenotype of dystrophinopathy in old mdx mice. Anat Rec 242:70-76.
189. Lesko LJ, Rowland M, Peck CC, Blaschke TF, Breimer D, de Jong HJ, Grahnen A, Kuhlmann JJ, Stewart B. 2000. Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans. Eur J Pharm Sci 10:iv-xiv.
190. Lin JH. 1995. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23:1008-1021.
191. Lis Y, Roberts MH, Kamble S, J Guo J, Raisch DW. 2012. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: Report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group. Value Health 15:1108-1118.
192. Liu JMK, Okamura CS, Bogan DJ, Bogan JR, Childers MK, Kornegay JN. 2004. Effects of prednisone in canine muscular dystrophy. Muscle Nerve 30:767-773.
193. Malhotra S, Hart K, Klamut H, Thomas N, Bodrug S, Burghes A, Bobrow M, Harper P, Thompson M, Ray P, Worton R. 1988. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science 242:755-759.
194. Malik V, Rodino-Klapac LR, Mendell JR. 2012. Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs 17:261-277.
195. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, Morgan JE, Partridge TA, Wilton SD. 2001. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 98:42-47.
196. Manzur AY, Kuntzer T, Pike M, Swan A. 2008. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 1:CD003725.
197. Martin PT, Xu R, Rodino-Klapac LR, Oglesbay E, Camboni M, Montgomery CL, Shontz K, Chicoine LG, Clark KR, Sahenk Z, Mendell JR, Janssen PM. 2009. Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. Am J Physiol Cell Physiol 296:C476-488.
198. Maruo T, Nakatani S, Jin Y, Uemura K, Sugimachi M, Ueda-Ishibashi H, Kitakaze M, Ohe T, Sunagawa K, Miyatake K. 2007. Evaluation of transmural distribution of viable muscle by myocardial strain profile and dobutamine stress echocardiography. Am J Physiol Heart Circ Physiol 292: H921-H927.
199. Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, Torrente Y, D'Amico A, Doglio L, Viggiano E, D'Ambrosio P, Cavallaro F, Frosini S, Bello L, Bonfiglio S, De Sanctis R, Rolle E, Bianco F, Magri F, Rossi F, Vasco G, Vita G, Motta MC, Donati MA, Sacchini M, Mongini T, Pini A, Battini R, Pegoraro E, Previtali S, Napolitano S, Bruno C, Politano L, Comi GP, Bertini E, Mercuri E. 2013. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One 8:e52512.
200. McComas AJ, Preswick G, Garner S. 1988. The sick motoneurone hypothesis of muscular dystrophy. Prog Neurobiol 30:309-331.
201. McComas AJ, Sica REP, Currie S. 1970. Muscular dystrophy. Evidence for a neural factor. Nature 226:1263-1264.
202. McDonald CM, Abresch RT, Carter GT, Fowler WM Jr, Johnson ER, Kilmer DD, Sigford BJ. 1995. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 74:S70-S92.
203. McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, Glanzman AM; PTC124-GD-007-DMD Study Group, Spiegel R, Barth J, Elfring G, Reha A, Peltz S. 2013a. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48:343-356.
204. McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, Glanzman AM; PTC124-GD-007-DMD Study Group, Spiegel R, Barth J, Elfring G, Reha A, Peltz SW. 2013b. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48:357-368.
205. McDouall RM, Dunn MJ, Dubowitz. 1990. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 99:199-217.
206. McEntee K, Amory H, Pypendop B, Balligand M, Clercx, Michaux C, Robert JF, Gerard P, Pochet T, Henroteaux M. 1998. Effects of dobutamine on isovolumic and ejection phase indices of cardiac contractility in conscious healthy dogs. Res Vet Sci 64:45-80.
207. McPherron AC, Lawler AM, Lee S-J. 1997. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387:83-90.
208. Mendell JR, Engel WK, Derrer EC. 1971. Duchenne muscular dystrophy: Functional ischemia reproduces its characteristic lesions. Science 172:1143-1145.
209. Meregalli M, Farini A, Belicchi M, Parolini D, Cassinelli L, Razini P, Sitzia C, Torrente Y. 2013. Perspectives of stem cell therapy in Duchenne muscular dystrophy. FEBS J 280:4251-4262.
210. Messina S, Altavilla D, Aguennouz M, Seminara P, Minutoli L, Monici MC, Bitto A, Mazzeo A, Marini H, Squadrito F, Vita G. 2006b. Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 168:918-926.
211. Messina S, Bitto A, Aguennouz M, Mazzeo A, Migliorato A, Polito F, Irrera N, Altavilla D, Vita GL, Russo M, Naro A, De Pasquale MG, Rizzuto E, Musarò A, Squadrito F, Vita G. 2009. Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone. Exp Neurol 220:349-358.
212. Messina S, Bitto A, Aguennouz M, Minutoli L, Monici MC, Altavilla D, Squadrito F, Vita G. 2006a. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp Neurol 198:234-241.
213. Messina S, Bitto A, Aguennouz M, Vita GL, Polito F, Irrera N, Altavilla D, Marini H, Migliorato A, Squadrito F, Vita G. 2011.The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-α activation and ameliorates muscle function and morphology in mdx mice. Neuromuscul Disord 21:579-589.
214. Michels KB, Binder AM, Dedeurwaerder S, Epstein CB, Greally JM, Gut I, Houseman EA, Izzi B, Kelsey KT, Meissner A, Milosavljevic A, Siegmund KD, Bock C, Irizarry RA. 2013. Recommendations for the design and analysis of epigenome-wide association studies. Nat Methods 10:949-955.
215. Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G, Sweeney HL, Robbins J, Molkentin JD. 2008. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 14:442-447.
216. Miller JB, GirgenrathM. 2006. The role of apoptosis in neuromuscular diseases and prospects for anti-apoptosis therapy. TrendsMol Med 12:279-286.
217. Miura P, Jasmin BJ. 2006. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: How close are we? Trends Mol Med 12:122-129.
218. Mizuno Y, Nonaka I, Hirai S, Ozawa E. 1993. Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects. J Neurol Sci 119:43-52.
219. Mok E, Constantin B, Favreau F, Neveux N, Magaud C, Delwail A, Hankard R. 2008. l-Glutamine administration reduces oxidized glutathione and MAP kinase signaling in dystrophic muscle of mdx mice. Pediatr Res 63:268-273.
220. Monici MC, Aguennouz M, Mazzeo A, Messina C, Vita G. 2003. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 60:993-997.
221. Moorwood C, Soni N, Patel G, Wilton SD, Khurana TS. 2013. A cell-based high-throughput screening assay for posttranscriptional utrophin upregulation. J Biomol Screen 18:400-406.
222. Morales MG, Vazquez Y, Acuña MJ, Rivera JC, Simon F, Salas JD, Alvarez Ruf J, Brandan E, Cabello-Verrugio C. 2012. Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int J Biochem Cell Biol 44:1993-2002.
223. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, Ostrander EA. 2007. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007;3:779-786.
224. Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K. 2010. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 25:1116-1129.
225. Mozzetta C, Consalvi S, Saccone V, Tierney M, Diamantini A, Mitchell KJ, Marazzi G, Borsellino G, Battistini L, Sassoon D, Sacco A, Puri PL. 2013. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice. EMBO Mol Med 5:626-639.
226. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. 2000. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35:193-201.
227. Nagaraju K, Willmann R, TREAT-NMD Network and theWellstone Muscular Dystrophy Cooperative Research Network. 2009. Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: Report of two expert workshops on ''Pre-clinical testing for Duchenne dystrophy'': Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008. Neuromuscul Disord 19:502-506.
228. Nakae Y, Dorchies OM, Stoward PJ, Zimmermann BF, Ritter C, Ruegg UT. 2012. Quantitative evaluation of the beneficial effects in the mdx mouse of epigallocatechin gallate, an antioxidant polyphenol from green tea. Histochem Cell Biol 137:811-827.
229. National Research Council. 1985. Models for Biomedical Research. A New Perspective. Washington DC: The National Academies Press.
230. National Research Council. 1998. Biomedical Models and Resources: Current Needs and Future Opportunities. Washington DC: The National Academies Press.
231. Nelson CA, Hunter RB, Quigley LA, Girgenrath S, Weber WD, McCullough JA, Dinardo CJ, Keefe KA, Ceci L, Clayton NP, McVie-Wylie A, Cheng SH, Leonard JP, Wentworth BM. 2011. Inhibiting TGF-β activity improves respiratory function in mdx mice. Am J Pathol 178:2611-2621.
232. Ng R, Metzger JM, Claflin DR, Faulkner JA. 2008. Poloxamer 188 reduces the contraction-induced force decline in lumbrical muscles from mdx mice. Am J Physiol Cell Physiol 295:C146-150.
233. Nghiem PP, Hoffman EP, Mittal P, Brown KJ, Schatzberg SJ, Ghimbovschi S, Wang Z, Kornegay JN. 2013. Sparing of the dystrophin-deficient cranial sartorius muscle is associated with classical and novel hypertrophy pathways in GRMD dogs. Am J Pathol 183:1411-1424.
234. Nguyen TM, Ellis JM, Love DR, Davies KE, Gatter KC, Dickson G, Morris GE. 1991. Localization of the DMDL gene-encoded dystrophinrelated protein using a panel of nineteen monoclonal antibodies: Presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines. J Cell Biol 115:1695-1700.
235. Nicholson LV. 1993a. The "rescue" of dystrophin synthesis in boys with Duchenne muscular dystrophy. Neuromuscul Disord 3:525-531.
236. Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D. 1993b. Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy. Arch Dis Child 68:632-636.
237. Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D, Curtis A, Ginjaar IB, den Dunnen JT, Welch JL, Butler TJ, Bakker E, van Ommen G-JB, Harris JB. 1993c. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups. J Med Genet 30:728-736.
238. Nonneman DJ, Brown-Brandl T, Jones SA, Wiedmann RT, Rohrer GA. 2012. A defect in dystrophin causes a novel porcine stress syndrome. BMC Genomics 13:233.
239. Nudelman I, Rebibo-Sabbah A, Cherniavsky M, Belakhov V, Hainrichson M, Chen F, Schacht J, Pilch DS, Ben-Yosef T, Baasov T. 2009. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 52:2836-2845.
240. Pan Y, Chen C, Shen Y, Zhu CH, Wang G, Wang XC, Chen HQ, Zhu MS. 2008. Curcumin alleviates dystrophic muscle pathology in mdx mice. Mol Cells 25:531-537.
241. Partridge T. 2010. The potential of exon skipping for treatment for Duchenne muscular dystrophy. J Child Neurol 25:1165-1170.
242. Partridge TA. 2013. The mdx mouse model as a surrogate for Duchenne muscular dystrophy. FEBS J 280:4177-4186.
243. Passaquin AC, Metzinger L, Léger JJ, Warter JM, Poindron P. 1993. Prednisolone enhances myogenesis and dystrophin-related protein in skeletal muscle cell cultures from mdx mouse. J Neurosci Res 35:363-372.
244. Passerini L, Bernasconi P, Baggi F, Confalonieri P, Cozzi F, Cornelio F, Mantegazza R. 2002. Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. Neuromuscul Disord 12:828-835.
245. Patronek GJ, Waters DJ, Glickman LT. 1997. Comparative longevity of pet dogs and humans: implications for gerontology research. J Gerontol A Biol Sci Med Sci 52:B171-178.
246. Pearce GW, Walton JN. 1962. Progressive muscular dystrophy: The histopathological changes in skeletal muscle obtained by biopsy. J Pathol Bacteriol 83:535-550.
247. Pegoraro E, Hoffman EP, Piva L, Gavassini BF, Cagnin S, Ermani M, Bello L, Soraru G, Pacchioni B, Bonifati MD, Lanfranchi G, Angelini C, Kesari A, Lee I, Gordish-Dressman H, Devaney JM, McDonald CM. 2011. Cooperative International Neuromuscular Research Group. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 76:219-226.
248. Peltz SW, Morsy M, Welch EM, Jacobson A. 2013. Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 64:407-425.
249. Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, Froehner SC. 2012. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol 228:77-87.
250. Peter AK, Marshall JL, Crosbie RH. 2008. Sarcospan reduces dystrophic pathology: Stabilization of the utrophin-glycoprotein complex. J Cell Biol. 183:419-427.
251. Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, Delfín DA, DiRienzo K, Clemens PR, Robbins PD, Baldwin AS, Flood P, Kaumaya P, Freitas M, Kornegay JN, Mendell JR, Rafael-Fortney JA, Guttridge DC, Janssen PM. 2011. Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. 2011. Mol Med 17:508-515.
252. Phillips MF, Quinlivan R. 2008. Calcium antagonists for Duchenne muscular dystrophy. Cochrane Database Syst Rev. CD004571 (updated in 2011, Issue 2).
253. Pigozzo SR, Da Re L, Romualdi C, Mazzara PG, Galletta E, Fletcher S, Wilton SD, Vitiello L. 2013. Revertant fibers in the mdx murine model of Duchenne muscular dystrophy: An age-and muscle-related reappraisal. PLoS One 8:e72147.
254. Plenge RM, Scolnick EM, Altshuler D. 2013. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 12:581-594.
255. Politano L, Nigro G, Nigro V, Piluso G, Papparella S, Paciello O, Comi LI. 2003. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 22:15-21.
256. Porter JD, Merriam AP, Leahy P, Gong B, Feuerman J, Cheng G, Khanna S. 2004. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. Hum Mol Genet 13:257-269.
257. Porter JD, Merriam AP, Leahy P, Gong B, Khanna S. 2003. Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum Mol Genet 12:1813-1821.
258. Prowse KR, Greider CW. 1995. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci U S A 92:4818-4822.
259. Pulido SM, Passaquin AC, Leijendekker WJ, Challet C, Wallimann T, Rüegg UT. 1998. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett 439:357-362.
260. Qiao C, Li J, Zheng H, Bogan J, Li J, Yuan Z, Zhang C, Bogan D, Kornegay J, Xiao X. 2009. Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther 20:1-10.
261. Qin LF, Wang WC, Fang H, Mao XZ, Huang GL, Chen Y, Zhou HD, Shen Y, Qin LH, Peng D. 2013. Expression of NF-κB and osteopontin of synovial fluid of patients with knee osteoarthritis. Asian Pac J Trop Med 6:379-382.
262. Quinn JL, Huynh T, Uaesoontrachoon K, Tatem K, Phadke A, Van der Meulen JH, Yu Q, Nagaraju K. 2013. Effects of dantrolene therapy on disease phenotype in dystrophin deficient mdx mice. PLoS Curr. 5pii: ecurrents.md.e246cf 493a7edb1669 f42fb 735936b46.
263. Radley HG, Grounds MD. 2006. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiol Dis. 2006:387-397.
264. Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, Ganguly R, Stangland JE, Tran T, Xu Y, Canan BD, Mays TA, Delfín DA, Janssen PM, Raman SV. 2011. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation 124:582-588.
265. Rasola A, Bernardi P. 2007. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis 12:815-833.
266. Reay DP, Yang M, Watchko JF, Daood M, O'Day TL, Rehman KK, Guttridge DC, Robbins PD, Clemens PR. 2011. Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol Dis 43:598-608.
267. Remus EW, Lyle AN, Weiss D, Landàzuri N, Weber M, Searles C, Taylor WR. 2013. miR181a protects against angiotensin II-induced osteopontin expression in vascular smooth muscle cells. Atherosclerosis 228:168-174.
268. Rennie MJ, Edwards RH, Millward DJ, Wolman SL, Halliday D, Matthews DE. 1982. Effects of Duchenne muscular dystrophy on muscle protein synthesis. Nature 296:165-167.
269. Rifai Z, Welle S, Moxley RT 3rd, Lorenson M, Griggs RC. 1995. Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol 268:E67-74.
270. Roberts R, McCune SK. 2008. Animal studies in the development of medical countermeasures. Clin Pharmacol Ther 83:918-920.
271. Rouger K, Larcher T, Dubreil L, Deschamps JY, Le Guiner C, Jouvion G, Delorme B, Lieubeau B, Carlus M, Fornasari B, Theret M, Orlando P, Ledevin M, Zuber C, Leroux I, Deleau S, Guigand L, Testault I, Le Rumeur E, Fiszman M, Chérel Y. 2011. Systemic delivery of allogenic muscle stem (MuStem) cells induces long-term muscle repair and clinical efficacy in Duchenne muscular dystrophy dogs. Am J Pathol 179:2501-2518.
272. Rowland LP. 1976. Pathogenesis of muscular dystrophies. Arch Neurol 33:315-321.
273. Ruegg UT. 2013. Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol 26:577-584.
274. Sacco A, Mourkioti F, Tran R, Choi J, Llewellyn M, Kraft P, Shkreli M, Delp S, Pomerantz JH, Artandi SE, Blau HM. 2010. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/ mTR mice. Cell 143:1059-1071.
275. Sali A, Guerron AD, Gordish-Dressman H, Spurney CF, Iantorno M, Hoffman EP, Nagaraju K. 2012. Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS One 7:e34204.
276. Salimena MC, Lagrota-Candido J, Quírico-Santos T. 2004. Gender dimorphism influences extracellular matrix expression and regeneration of muscular tissue in mdx dystrophic mice. Histochem Cell Biol 122:535-544.
277. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Innocenzi A, Mognol P, Thibaud JL, Galvez BG, Barthélémy I, Perani L, Mantero S, Guttinger M, Pansarasa O, Rinaldi C, Cusella De Angelis MG, Torrente Y, Bordingnon C, Bottinelli R, Cossu G. 2006. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444:574-579.
278. Sandri M, Coletto L, Grumati P, Bonaldo P. 2013. Misregulation of autophagy and protein degradation systems in myopathies and muscular dystrophies. J Cell Sci 126:5325-5333.
279. Schatzberg SJ, Anderson LV, Wilton SD, Kornegay JN, Mann CJ, Solomon GG, Sharp NJ. 1998. Alternative dystrophin gene transcripts in golden retriever muscular dystrophy. Muscle Nerve 21:991-998.
280. Schatzberg SJ, Olby NJ, Breen M, Anderson LVB, Langford CF, Dickens HF, Wilton SD, Zeiss CJ, Binns MM, Kornegay JN, Morris GE, Sharp NJH. 1999. Molecular analysis of a spontaneous dystrophin "knockout" dog. Neuromuscul Disord 9:289-295.
281. Schoenebeck JL, Ostrander EA. 2013. The genetics of canine skull shape variation. Genetics 193:317-325.
282. Selsby J, Pendrak K, Zadel M, Tian Z, Pham J, Carver T, Acosta P, Barton E, Sweeney HL. 2010. Leupeptin-based inhibitors do not improve the mdx phenotype. Am J Physiol Regul Integr Comp Physiol 299, R1192-1201.
283. Sena E, van der Worp HB, Howells D, Macleod M. 2007. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 30:433-439.
284. Serafin WE, Dement SH, Brandon S, Hill EJ, Park CR, Park JH. 1987. Interactions of vitamin E and penicillamine in the treatment of hereditary avian muscular dystrophy. Muscle Nerve 10:685-697.
285. Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S, Hung WY, Constantinou CD, Dykstra MJ, Roses AD, Bartlett RJ. 1992. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13:115-121.
286. Shavlakadze T, Chai J, Maley K, Cozens G, Grounds G, Winn N, Rosenthal N, Grounds MD. 2010. A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo. J Cell Sci 123:960-971.
287. Shcherbata HR, Yatsenko AS, Patterson L, Sood VD, Nudel U, Yaffe D, Baker D, Ruohola-Baker H. 2007. Dissecting muscle and neuronal disorders in a Drosophila model of muscular dystrophy. EMBO J 26:481-493.
288. Shimatsu Y, Katagiri K, Furuta T, Nakura M, Tanioka Y, Yuasa K, Tomohiro M, Kornegay JN, Nonaka I, Takeda S. 2003. Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim 52:93-97.
289. Shin J, Tajrishi MM, Ogura Y, Kumar A. 2013.Wasting mechanisms in muscular dystrophy. Int J Biochem Cell Biol 45:2266-2279.
290. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. 1989. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 244:1578-1580.
291. Siegel AL, Bledsoe C, Lavin J, Gatti F, Berge J, Millman G, Turin E, Winders WT, Rutter J, Palmeiri B, Carlson CG. 2009. Treatment with inhibitors of the NF-kappaB pathway improves whole body tension development in the mdx mouse. Neuromuscul Disord 19:131-139.
292. Siegel AS, Henley S, Zimmerman A, Miles M, Plummer R, Kurz J, Balch F, Rhodes JA, Shinn GL, Carlson CG. 2011. The influence of passive stretch and NF-κB inhibitors on the morphology of dystrophic muscle fibers. Anat Rec (Hoboken) 294:132-144.
293. Smith BF, Yue Y, Woods PR, Kornegay JN, Shin J-H, Williams RR, Duan D. 2011. An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Lab Invest 91:216-231.
294. Spencer MJ, Croall DE, Tidball JG. 1995. Calpains are activated in necrotic fibers from mdx dystrophic mice. J Biol Chem 270:10909-10914.
295. Spencer MJ, Mellgren RL. 2002. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum Mol Genet 11:2645-2655.
296. Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG. 2001. Helper (CD4[+]) and cytotoxic (CD8[+]) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 98:235-243.
297. Spurney C, Yu Q, Nagaraju K. 2011a. Speckle tracking analysis of the left ventricular anterior wall shows significantly decreased relative radial strain patterns in dystrophin deficient mice after 9 months of age. Version 2. PLoS Curr 3:RRN1273.
298. Spurney CF. 2011d. Cardiomyopathy of Duchenne muscular dystrophy: Current understanding and future directions. Muscle Nerve 44:8-19.
299. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, Van Der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, Hoffman EP, Nagaraju K. 2009. Preclinical drug trials in the mdx mouse: Assessment of reliable and sensitive outcome measures. Muscle Nerve 39:591-602.
300. Spurney CF, Guerron AD, Yu Q, Sali A, van der Meulen JH, Hoffman EP, Nagaraju K. 2011c. Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC Cardiovasc Disord 11:20.
301. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, Gordish-Dressman H, Rayavarapu S, van der Meulen J, Hoffman EP, Nagaraju K. 2011b. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 16:87-95.
302. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM. 1991. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352:536-539.
303. Steinman L. 2009. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 9:440-447.
304. Steward O, Popovich PG, Dietrich WD, Kleitman N. 2012. Replication and reproducibility in spinal cord injury research. Exp Neurol 233:597-605.
305. Su JB, Cazorla O, Blot S, Blanchard-Gutton N, Ait Mou Y, Barthélémy I, Sambin L, Sampedrano CC, Gouni V, Unterfinger Y, Aguilar P, Thibaud JL, Bizé A, Pouchelon JL, Dabiré H, Ghaleh B, Berdeaux A, Chetboul V, Lacampagne A, Hittinger L. 2012. Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy. Cardiovasc Res 95:86-96.
306. Summerton J, Weller D. 1997. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7:187-195.
307. Swimmer RA, Rozanski EA. 2011. Evaluation of the 6-minute walk test in pet dogs. J Vet Intern Med 25:405-406.
308. Tang Y, Reay DP, Salay MN, Mi MY, Clemens PR, Guttridge DC, Robbins PD, Huard J, Wang B. 2010. Inhibition of the IKK/NF-κB pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Ther 17:1476-1483.
309. Taniguti AP, Pertille A, Matsumura CY, Santo Neto H, Marques MJ. 2011. Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-β1 blocker. Muscle Nerve 43:82-87.
310. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, Victor RG. 1998. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A 95:15090-15095.
311. Tibbitts J. 2003. Issues related to the use of canines in toxicologic pathology-issues with pharmacokinetics and metabolism. Toxicol Pathol 31:17-24.
312. Tidball JG, Albrecht DE, Lokensgard BE, Spencer MJ. 1995. Apoptosis precedes necrosis of dystrophin-deficient muscle. J Cell Sci 108:2197-2204.
313. Tidball JG, Villalta SA. 2010. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 298:R1173-1187.
314. Tinsley JM, Fairclough RJ, Storer R, Wilkes FJ, Potter AC, Squire SE, Powell DS, Cozzoli A, Capogrosso RF, Lambert A, Wilson FX, Wren SP, De Luca A, Davies KE. 2011. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One 6;6: e19189.
315. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE. 1996. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384:349-353.
316. Townsend D, Turner I, Yasuda s, Martindale J, Davis J, Shillingford M, Kornegay JN, Metzger JM. 2010. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 120:1140-1150.
317. Tseng BS, Zhao P, Pattison JS, Gordon SE, Granchelli JA, Madsen RW, Folk LC, Hoffman EP, BoothFW. 2002. Regenerated mdx mouse skeletal muscle shows differential mRNA expression. J Appl Physiol 93:537-545.
318. Uaesoontrachoon K, Wasgewatte Wijesinghe DK, Mackie EJ, Pagel CN. 2013. Osteopontin deficiency delays inflammatory infiltration and the onset of muscle regeneration in a mouse model of muscle injury. Dis Model Mech 6:197-205.
319. Urtasun R, Lopategi A, George J, Leung TM, Lu Y, Wang X, Ge X, Fiel MI, Nieto N. 2012. Osteopontin, an oxidant stress sensitive cytokine, upregulates collagen-I via integrin a(V)β(3) engagement and PI3 K/pAkt/ NFκB signaling. Hepatology 55:594-608.
320. Valentine BA, Cooper BJ, Cummings JF, de Lahunta A. 1990. Canine X-linked muscular dystrophy: morphologic lesions. J Neurol Sci 97:1-23.
321. Valentine BA, Cooper BJ, de Lahunta A, O'Quinn R, Blue JT. 1988. Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: Clinical studies. J Neurol Sci 88:69-81.
322. Valentine BA, Cooper BJ, Gallagher EA. 1989. Intracellular calcium in canine muscle biopsies. J Comp Pathol 223-230.
323. Vandenburgh H, Shansky J, Benesch-Lee F, Skelly K, Spinazzola JM, Saponjian Y, Tseng BS. 2009. Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts. FASEB J 23:3325-3334.
324. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, Miceli MC, Spencer MJ. 2009. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 119:1583-1594.
325. Vignos PJ Jr, Spencer GE Jr, Archibald JC. 1963. Management of muscular dystrophy of childhood. JAMA 184:89-96.
326. Vulin A, Barthélémy I, Goyenvalle A, Thibaud JL, Beley C, Griffith G, Benchaouir R, le Hir M, Unterfinger Y, Lorain S, Dreyfus P, Voit T, Carlier P, Blot S, Garcia L. 2012. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 20:2120-2133.
327. Wadosky KM, Li L, Rodríguez JE, Min J, Bogan D, Gonzalez J, Kornegay JN, Willis M. 2011. Regulation of the calpain and ubiquitin proteasome systems in a canine model of Duchenne muscular dystrophy. Muscle Nerve 44:553-562.
328. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR. 2008. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63:561-571.
329. Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, Hoffman EP, Fischbeck KH. 2001. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 49:706-711.
330. Wagner KR, Liu X, Chang X, Allen RE. 2005. Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci U S A 102:2519-2524.
331. Wagner KR, McPherron AC, Winik N, Lee SJ. 2002. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52:832-836.
332. Walker DK. 2004. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol 58:601-608.
333. Walmsley GL, Arechavala-Gomeza V, Fernandez-Fuente M, Burke MM, Nagel N, Holder A, Stanley R, Chandler K, Marks SL, Muntoni F, Shelton GD, Piercy RJ. 2010. A Duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient Cavalier King Charles Spaniels is amenable to exon 51 skipping. PloS One 5:e8647.
334. Wang B, Li J, Xiao X. 2000. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A 97:13714-13719.
335. Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ, Chamberlain JS, Kuhr CS. 2007. Immunity to adeno-associated virusmediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 18:18-26.
336. Webster C, Blau HM. 1990. Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: Implications for cell and gene therapy. Somat Cell Mol Genet 16:557-565.
337. Webster C, Silberstein L, Hays AP, Blau HM. 1988. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 52:503-513.
338. Wehling-Henricks M, Lee JJ, Tidball JG. 2004. Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle. Neuromuscul Disord 14:483-490.
339. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. 2007. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87-91.
340. Weller B, Massa R, Karpati G, Carpenter S. 1991. Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles. Muscle Nerve 14:771-774.
341. Whitehead NP, Pham C, Gervasio OL, Allen DG. 2008. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J Physiol 586:2003-2014.
342. Willmann R, De Luca A, Benatar M, Grounds M, Dubach J, Raymackers JM, Nagaraju K; TREAT-NMD Neuromuscular Network. 2012. Enhancing translation: Guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul Disord 22:43-49.
343. Willmann R, Possekel S, Dubach-Powell J, Meier T, Ruegg MA. 2009. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 19:241-249.
344. Wilson LA, Cooper BJ, Dux L, Dubowitz V, Sewry CA. 1994. Expression of utrophin (dystrophin-related protein) during regeneration and maturation of skeletal muscle in canine X-linked muscular dystrophy. Neuropathol Appl Neurobiol 20:359-367.
345. Yang Q, Tang Y, Imbrogno K, Lu A, Proto JD, Chen A, Guo F, Fu FH, Huard J, Wang B. 2102. AAV-based shRNA silencing of NF-κB ameliorates muscle pathologies in mdx mice. Gene Ther 19:1196-1204.
346. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, Hoffman E. 2009. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65:667-676.
347. Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, Echigoya Y, Partridge T, Hoffman EP, Takeda S. 2012. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 22: 306-315.
348. Yu S, Zheng L, Li Y, Li C, Ma C, Li Y, Li X, Hao P. 2012. A cross-species analysis method to analyze animal models' similarity to human's disease state. BMC Syst Biol 6:S18.
349. Yuasa K, Miyagoe Y, Yamamoto K, Nabeshima Y, Dickson G, Takeda S. 1998. Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett 425:329-336.
350. Yuasa K, Yoshimura M, Urasawa N, Ohshima S, Howell JM, Nakamura A, Hijikata T, Miyagoe-Suzuki Y, Takeda S. 2007. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 14:1249-1260.
351. Yugeta N, Urasawa N, Fujii Y, YoshimuraM, Yuasa K, Wada MR, NakuraM, Shimatsu Y, Tomohiro M, Takahashi A, Machida N, Wakao Y, Nakaura A, Takeda S. 2006. Cardiac involvement in Beagle-based canine x-linked muscular dystrophy in Japan (CXMDJ): Electrocardiographic, echocardiographic, and morphologic studies. BMC Cardiovasc Disord 6:47-59.
352. Zhang J, Xu Y, Pan L, Chen T, Chen Z, Zhao R. 2010. Effect of simvastatin on collagen I deposition in non-infarcted myocardium: Role of NF-κB and osteopontin. Can J Physiol Pharmacol 88:1026-1034.
353. Ziter FA, Allsop KG, Tyler FH. 1977. Assessment of muscle strength in Duchenne muscular dystrophy. Neurology 27:981-984.
354. Zucconi E, Valadares MC, Vieira NM, Bueno CR Jr, Secco M, Jazedje T, da Silva HC, Vainzof M, Zatz M. 2010. Ringo: Discordance between the molecular and clinical manifestation in a golden retriever muscular dystrophy dog. Neuromuscul Disord. 20:64-70.